This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using NovoPen® 4 under normal clinical practice conditions.

Inclusion Criteria:

• Any subject with Type 1 or Type 2 diabetes and accepting to use NovoPen® 4. The selection will be at the discretion of the individual physician.
• A study specific signed informed consent must be signed by each subject before any study-related activities or information is collected, if required by local regulations

Exclusion Criteria:

• Subjects who are unlikely to comply with the protocol, e.g., unwillingness to cooperate, inability to return for the final visit
• Subjects with known or suspected allergy to any insulin or any of its excipients

Any subject with Type 1 or Type 2 diabetes